Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Buys

Showing results (241-250 of 322) with videos related to

Pageof 33
Sort By:
JAMA|June 7, 2011
Effect of screening on ovarian cancer mortality: the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Randomized Controlled TrialSaundra S Buys, Edward Partridge, Amanda Black, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|April 8, 2020
NCCN Guidelines Insights: Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 1.2020Mary B Daly, Robert Pilarski, Matthew B Yurgelun, et al.
Human Genetics|October 1, 2011
Fine mapping of 14q24.1 breast cancer susceptibility locusPhoebe Lee, Yi-Ping Fu, Jonine D Figueroa, et al.
Cancer Discovery|July 23, 2014
Rare mutations in RINT1 predispose carriers to breast and Lynch syndrome-spectrum cancersDaniel J Park, Kayoko Tao, Florence Le Calvez-Kelm, et al.
BJU International|June 5, 2024
The psychosocial impact of prostate cancer screening for BRCA1 and BRCA2 carriersElizabeth K Bancroft, Elizabeth C Page, Mark N Brook, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|January 6, 2021
Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 2.2021, NCCN Clinical Practice Guidelines in OncologyMary B Daly, Tuya Pal, Michael P Berry, et al.
Breast Cancer Research and Treatment|April 28, 2016
An international survey of surveillance schemes for unaffected BRCA1 and BRCA2 mutation carriersDana Madorsky-Feldman, Miri Sklair-Levy, Tamar Perri, et al.
Breast Cancer Research and Treatment|September 27, 2012
Evaluation of chromosome 6p22 as a breast cancer risk modifier locus in a follow-up study of BRCA2 mutation carriersKristen N Stevens, Xianshu Wang, Zachary Fredericksen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 2, 2017
Early Detection of Ovarian Cancer using the Risk of Ovarian Cancer Algorithm with Frequent CA125 Testing in Women at Increased Familial Risk - Combined Results from Two Screening TrialsSteven J Skates, Mark H Greene, Saundra S Buys, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 7, 2013
Tamoxifen and risk of contralateral breast cancer for BRCA1 and BRCA2 mutation carriersKelly-Anne Phillips, Roger L Milne, Matti A Rookus, et al.
Pageof 33

Showing results (241-250 of 322) with videos related to

Sort By:
Pageof 33
JAMA|June 7, 2011
Effect of screening on ovarian cancer mortality: the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Randomized Controlled TrialSaundra S Buys, Edward Partridge, Amanda Black, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|April 8, 2020
NCCN Guidelines Insights: Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 1.2020Mary B Daly, Robert Pilarski, Matthew B Yurgelun, et al.
Human Genetics|October 1, 2011
Fine mapping of 14q24.1 breast cancer susceptibility locusPhoebe Lee, Yi-Ping Fu, Jonine D Figueroa, et al.
Cancer Discovery|July 23, 2014
Rare mutations in RINT1 predispose carriers to breast and Lynch syndrome-spectrum cancersDaniel J Park, Kayoko Tao, Florence Le Calvez-Kelm, et al.
BJU International|June 5, 2024
The psychosocial impact of prostate cancer screening for BRCA1 and BRCA2 carriersElizabeth K Bancroft, Elizabeth C Page, Mark N Brook, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|January 6, 2021
Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 2.2021, NCCN Clinical Practice Guidelines in OncologyMary B Daly, Tuya Pal, Michael P Berry, et al.
Breast Cancer Research and Treatment|April 28, 2016
An international survey of surveillance schemes for unaffected BRCA1 and BRCA2 mutation carriersDana Madorsky-Feldman, Miri Sklair-Levy, Tamar Perri, et al.
Breast Cancer Research and Treatment|September 27, 2012
Evaluation of chromosome 6p22 as a breast cancer risk modifier locus in a follow-up study of BRCA2 mutation carriersKristen N Stevens, Xianshu Wang, Zachary Fredericksen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 2, 2017
Early Detection of Ovarian Cancer using the Risk of Ovarian Cancer Algorithm with Frequent CA125 Testing in Women at Increased Familial Risk - Combined Results from Two Screening TrialsSteven J Skates, Mark H Greene, Saundra S Buys, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 7, 2013
Tamoxifen and risk of contralateral breast cancer for BRCA1 and BRCA2 mutation carriersKelly-Anne Phillips, Roger L Milne, Matti A Rookus, et al.
Pageof 33